Literature DB >> 2301716

Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer?

N Kaibara1, K Sumi, M Yonekawa, M Ohta, M Makino, O Kimura, H Nishidoi, S Koga.   

Abstract

The results of surgical treatment of patients with advanced gastric cancer were analyzed retrospectively in terms of the extent of dissection of lymph nodes. The postoperative 5-year survival rate was 50.3% for 160 patients who had undergone potentially curative surgery with dissection of group 1, 2, and 3 lymph nodes (R3), compared with 48.8% for 185 patients with dissection of group 1 and 2 lymph nodes (R2). There was no difference in terms of survival between the two groups of patients. Of 160 patients receiving R3, 19 (11.9%) were found to be positive for metastasis to group 3 lymph nodes, and only 5 survived for more than 5 years after surgery (postoperative 5-year survival rate of 26.3%). In four of these five patients, metastases in the group 3 lymph nodes were confined to nodes in the hepatoduodenal ligament. Thus, it appears that in dissection of the deepest nodes, lymph nodes in the hepatoduodenal ligament are the most important to remove in the surgical treatment of advanced gastric cancer.

Entities:  

Mesh:

Year:  1990        PMID: 2301716     DOI: 10.1016/s0002-9610(05)80265-x

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Does the extent of lymph node dissection affect the postoperative survival of patients with gastric cancer and disseminating peritoneal metastasis?

Authors:  M Maeta; A Sugesawa; M Ikeguchi; S Tsujitani; H Yamashiro; S Shibata; A Kondo; N Kaibara
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

2.  Prognostic significance of p53 protein expression in early gastric cancer.

Authors:  Andrea Rodrigues Gonçalves; Antonio Jose Vasconcellos Carneiro; Ivanir Martins; Paulo Antonio Silvestre de Faria; Maria Aparecida Ferreira; Eduardo Linhares Riello de Mello; Homero Soares Fogaça; Celeste Carvalho Siqueira Elia; Heitor Siffert Pereira de Souza
Journal:  Pathol Oncol Res       Date:  2010-11-30       Impact factor: 3.201

3.  Gastric cancer: a curable disease in Britain.

Authors:  H M Sue-Ling; D Johnston; I G Martin; M F Dixon; M R Lansdown; M J McMahon; A T Axon
Journal:  BMJ       Date:  1993-09-04

Review 4.  Extended lymph node dissection (D2 resection) should now be performed routinely in the curative surgical treatment of gastric carcinoma.

Authors:  D Ravichandran; M Lamah; N J Carty; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1995-11       Impact factor: 1.891

5.  Curative surgery for gastric cancer: study of 166 consecutive patients.

Authors:  J C de Almeida; A Bettencourt; C S Costa; J M de Almeida
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

6.  Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.

Authors:  W Yu; I Whang; I Suh; A Averbach; D Chang; P H Sugarbaker
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

7.  Lymphangitis carcinomatosis of the lesser omentum: a prognostic factor in gastric cancer.

Authors:  G Wetscher; E Bodner; E Redmond; G Perdikis; M Gadenstätter; P Klingler; R Pointner
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

8.  Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview.

Authors:  Paul H Sugarbaker
Journal:  Pleura Peritoneum       Date:  2017-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.